{"transactions":[{"id":710220,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-07-15T01:45:05.000Z","date":"2026-07-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among XOMA Royalty Corporation (the \"Issuer\"), Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the \"Merger\"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the \"Issuer\" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award (\"PSU\") automatically converted into and was substituted with a restricted stock unit award (each, a \"Converted PSU\") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the \"Target Shares\" (as the term \"Target Shares\" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of \"Target Shares\" as to which, as of immediately prior to the Effective Time, the \"Performance-Requirement\" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the \"Target Shares\" underlying such PSU as to which the \"Performance-Requirement\" would be satisfied if the \"Closing Price\" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued from footnote 4) (B) the number of \"Target Shares\" as to which, as of immediately prior to the Effective Time, the \"Performance-Requirement\" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among XOMA Royalty Corporation (the \"Issuer\"), Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the \"Merger\"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the \"Issuer\" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award (\"PSU\") automatically converted into and was substituted with a restricted stock unit award (each, a \"Converted PSU\") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the \"Target Shares\" (as the term \"Target Shares\" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of \"Target Shares\" as to which, as of immediately prior to the Effective Time, the \"Performance-Requirement\" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the \"Target Shares\" underlying such PSU as to which the \"Performance-Requirement\" would be satisfied if the \"Closing Price\" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) (B) the number of \"Target Shares\" as to which, as of immediately prior to the Effective Time, the \"Performance-Requirement\" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU."}],"balance_after":0,"derivative":{"expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001193125-26-303720","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/791908/000119312526303720/ownership.xml","form_type":"4"}},{"id":710219,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-07-15T01:45:05.000Z","date":"2026-07-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":126924,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among XOMA Royalty Corporation (the \"Issuer\"), Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the \"Merger\"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the \"Issuer\" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award (\"PSU\") automatically converted into and was substituted with a restricted stock unit award (each, a \"Converted PSU\") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the \"Target Shares\" (as the term \"Target Shares\" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of \"Target Shares\" as to which, as of immediately prior to the Effective Time, the \"Performance-Requirement\" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the \"Target Shares\" underlying such PSU as to which the \"Performance-Requirement\" would be satisfied if the \"Closing Price\" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued from footnote 4) (B) the number of \"Target Shares\" as to which, as of immediately prior to the Effective Time, the \"Performance-Requirement\" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among XOMA Royalty Corporation (the \"Issuer\"), Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the \"Merger\"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the \"Issuer\" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award (\"PSU\") automatically converted into and was substituted with a restricted stock unit award (each, a \"Converted PSU\") with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the \"Target Shares\" (as the term \"Target Shares\" is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of \"Target Shares\" as to which, as of immediately prior to the Effective Time, the \"Performance-Requirement\" has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the \"Target Shares\" underlying such PSU as to which the \"Performance-Requirement\" would be satisfied if the \"Closing Price\" (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) (B) the number of \"Target Shares\" as to which, as of immediately prior to the Effective Time, the \"Performance-Requirement\" has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU."}],"balance_after":0,"derivative":{"expiration_date":"2029-03-11","underlying":"Common Stock","underlying_shares":126924},"source":{"system":"sec-edgar","filing":"0001193125-26-303720","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/791908/000119312526303720/ownership.xml","form_type":"4"}},{"id":710218,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-15T01:45:05.000Z","date":"2026-07-14","kind":"other","planned":false,"acquired":false,"shares":103906,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among XOMA Royalty Corporation (the \"Issuer\"), Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the \"Merger\"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the \"Issuer\" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the time the Merger became effective (the \"Effective Time\"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the \"Shares\") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the \"Closing Amount\"), plus (ii) an amount of contingent value rights (each, a \"CVR\") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the \"Merger Consideration\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (\"RSU\") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the \"Merger Agreement\"), by and among XOMA Royalty Corporation (the \"Issuer\"), Ligand Pharmaceuticals Incorporated (\"Parent\"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), and XOMA Royalty Holdings Corporation (\"HoldCo\"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the \"Merger\"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the \"Issuer\" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the time the Merger became effective (the \"Effective Time\"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the \"Shares\") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the \"Closing Amount\"), plus (ii) an amount of contingent value rights (each, a \"CVR\") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (\"RSU\") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-303720","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000119312526303720/ownership.xml","form_type":"4"}},{"id":803394,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-04-22T20:30:12.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's common stock (the \"Common Stock\").  The PSUs vest upon the Common Stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's common stock (the \"Common Stock\").  The PSUs vest upon the Common Stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":126924,"derivative":{"expiration_date":"2029-03-11","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001214659-26-004971","document":"marketforms-72954.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/791908/000121465926004971/marketforms-72954.xml","form_type":"4"}},{"id":803393,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-22T20:30:12.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":103906,"source":{"system":"sec-edgar","filing":"0001214659-26-004971","document":"marketforms-72954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000121465926004971/marketforms-72954.xml","form_type":"4"}},{"id":808453,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-04-15T22:13:17.000Z","date":"2026-04-13","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's common stock (the \"Common Stock\").  The PSUs vest upon the Common Stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's common stock (the \"Common Stock\").  The PSUs vest upon the Common Stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":26000,"derivative":{"expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001214659-26-004709","document":"marketforms-72918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/791908/000121465926004709/marketforms-72918.xml","form_type":"4"}},{"id":808452,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-15T22:13:17.000Z","date":"2026-04-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1632,"price":36.76,"value":59992.32,"ownership":{"direct":true},"balance_after":92368,"source":{"system":"sec-edgar","filing":"0001214659-26-004709","document":"marketforms-72918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/791908/000121465926004709/marketforms-72918.xml","form_type":"4"}},{"id":808451,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-15T22:13:17.000Z","date":"2026-04-13","kind":"exercise","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":94000,"source":{"system":"sec-edgar","filing":"0001214659-26-004709","document":"marketforms-72918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000121465926004709/marketforms-72918.xml","form_type":"4"}},{"id":844876,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-03-13T23:09:29.000Z","date":"2026-03-11","kind":"grant","planned":false,"acquired":true,"shares":138462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of common stock. The PSUs vest upon the common stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of common stock. The PSUs vest upon the common stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of common stock. The PSUs vest upon the common stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":138462,"derivative":{"underlying":"Common Stock","underlying_shares":138462},"source":{"system":"sec-edgar","filing":"0001214659-26-003284","document":"marketforms-72531.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/791908/000121465926003284/marketforms-72531.xml","form_type":"4"}},{"id":844875,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-13T23:09:29.000Z","date":"2026-03-11","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units payable solely in common stock that will vest as to 25% on each of the first four anniversaries of January 12, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001214659-26-003284","document":"marketforms-72531.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000121465926003284/marketforms-72531.xml","form_type":"4"}},{"id":939695,"issuer":{"id":30207,"kind":"organization","name":"XOMA Royalty Corp","symbol":"XOMA"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2026-01-14T21:35:07.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of XOMA common stock.  The PSUs vest upon XOMA's common stock achieving a specified price per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of XOMA common stock.  The PSUs vest upon XOMA's common stock achieving a specified price per share."}],"balance_after":30000,"derivative":{"expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001214659-26-000477","document":"marketforms-71833.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/791908/000121465926000477/marketforms-71833.xml","form_type":"4"}},{"id":1621644,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-23T22:00:15.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":100000,"derivative":{"exercise_price":17.54,"expiration_date":"2034-02-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-019458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024019458/ownership.xml","form_type":"4"}},{"id":1621643,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-23T22:00:15.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest on an annual basis over four years."}],"balance_after":133919,"source":{"system":"sec-edgar","filing":"0000950170-24-019458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024019458/ownership.xml","form_type":"4"}},{"id":1700565,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-22T22:30:09.000Z","date":"2023-12-21","kind":"sale","planned":false,"acquired":false,"shares":1920,"price":8.5,"value":16320.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":83919,"source":{"system":"sec-edgar","filing":"0000950170-23-072754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023072754/ownership.xml","form_type":"4"}},{"id":1703095,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-20T23:00:07.000Z","date":"2023-12-18","kind":"sale","planned":false,"acquired":false,"shares":398,"price":8.22,"value":3271.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":85839,"source":{"system":"sec-edgar","filing":"0000950170-23-071985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023071985/ownership.xml","form_type":"4"}},{"id":1711994,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-14T01:00:07.000Z","date":"2023-12-12","kind":"sale","planned":false,"acquired":false,"shares":1926,"price":7.81,"value":15042.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":86237,"source":{"system":"sec-edgar","filing":"0000950170-23-070143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023070143/ownership.xml","form_type":"4"}},{"id":1834988,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-07-06T01:27:47.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":2340,"price":9.08,"value":21247.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the \"ESPP\"), for the purchase period of January 1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 1, 2023."}],"balance_after":88163,"source":{"system":"sec-edgar","filing":"0000950170-23-031858","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023031858/ownership.xml","form_type":"4"}},{"id":1847402,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-21T20:17:31.000Z","date":"2023-06-20","kind":"sale","planned":false,"acquired":false,"shares":399,"price":12.94,"value":5163.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":85823,"source":{"system":"sec-edgar","filing":"0000950170-23-029158","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023029158/ownership.xml","form_type":"4"}},{"id":1855422,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-14T20:35:35.000Z","date":"2023-06-12","kind":"sale","planned":false,"acquired":false,"shares":319,"price":13.11,"value":4182.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":86222,"source":{"system":"sec-edgar","filing":"0000950170-23-027985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023027985/ownership.xml","form_type":"4"}},{"id":1883959,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-19T20:44:19.000Z","date":"2023-05-18","kind":"sale","planned":false,"acquired":false,"shares":399,"price":8.76,"value":3495.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":86541,"source":{"system":"sec-edgar","filing":"0000899243-23-013358","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924323013358/doc4.xml","form_type":"4"}},{"id":1890915,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-16T21:28:00.000Z","date":"2023-05-12","kind":"sale","planned":false,"acquired":false,"shares":347,"price":8.78,"value":3046.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":86940,"source":{"system":"sec-edgar","filing":"0000950170-23-022548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023022548/ownership.xml","form_type":"4"}},{"id":1916208,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-20T20:34:34.000Z","date":"2023-04-18","kind":"sale","planned":false,"acquired":false,"shares":398,"price":10.71,"value":4262.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":87287,"source":{"system":"sec-edgar","filing":"0000950170-23-013702","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017023013702/ownership.xml","form_type":"4"}},{"id":1919346,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-14T22:35:17.000Z","date":"2023-04-12","kind":"sale","planned":false,"acquired":false,"shares":318,"price":10.22,"value":3249.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":87685,"source":{"system":"sec-edgar","filing":"0000899243-23-011298","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924323011298/doc4.xml","form_type":"4"}},{"id":1937606,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-27T20:05:30.000Z","date":"2023-03-20","kind":"sale","planned":false,"acquired":false,"shares":399,"price":11.32,"value":4516.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":88003,"source":{"system":"sec-edgar","filing":"0000899243-23-009718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924323009718/doc4.xml","form_type":"4"}},{"id":2002751,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-22T00:01:31.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":93500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":93500,"derivative":{"exercise_price":11.34,"expiration_date":"2033-02-16","underlying":"Common Stock","underlying_shares":93500},"source":{"system":"sec-edgar","filing":"0000899243-23-005736","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924323005736/doc4.xml","form_type":"4"}},{"id":2002750,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-22T00:01:31.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":88402,"source":{"system":"sec-edgar","filing":"0000899243-23-005736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924323005736/doc4.xml","form_type":"4"}},{"id":2059781,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-06T18:48:02.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":201,"price":8.97,"value":1802.97,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the \"ESPP\"), for the purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on December 30, 2022."}],"balance_after":41402,"source":{"system":"sec-edgar","filing":"0000899243-23-001157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924323001157/doc4.xml","form_type":"4"}},{"id":2213756,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-07-05T22:08:59.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":1451,"price":10.9,"value":15815.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the \"ESPP\"), for the purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022."}],"balance_after":41201,"source":{"system":"sec-edgar","filing":"0000899243-22-025080","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322025080/doc4.xml","form_type":"4"}},{"id":2393790,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:43:51.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":75000,"derivative":{"exercise_price":13.6,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-22-006412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322006412/doc4.xml","form_type":"4"}},{"id":2393789,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-15T21:43:51.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":39750,"source":{"system":"sec-edgar","filing":"0000899243-22-006412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322006412/doc4.xml","form_type":"4"}},{"id":2540183,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-18T20:15:26.000Z","date":"2021-10-15","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares vested on September 8, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":229891,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000899243-21-040454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321040454/doc4.xml","form_type":"4"}},{"id":2540182,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-18T20:15:26.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":8000,"price":25,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021."}],"balance_after":2250,"source":{"system":"sec-edgar","filing":"0000899243-21-040454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321040454/doc4.xml","form_type":"4"}},{"id":2540181,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-18T20:15:26.000Z","date":"2021-10-15","kind":"exercise","acquired":true,"shares":8000,"price":4.3,"value":34400.0,"ownership":{"direct":true},"balance_after":10250,"source":{"system":"sec-edgar","filing":"0000899243-21-040454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321040454/doc4.xml","form_type":"4"}},{"id":2574268,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-09T20:15:18.000Z","date":"2021-09-08","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares vested on September 8, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":237891,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-21-035417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321035417/doc4.xml","form_type":"4"}},{"id":2574267,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-09T20:15:18.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":9513,"price":28.85,"value":274450.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.40 to $29.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":2250,"source":{"system":"sec-edgar","filing":"0000899243-21-035417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321035417/doc4.xml","form_type":"4"}},{"id":2574266,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-09T20:15:18.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":5487,"price":27.83,"value":152703.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.40 to $28.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":11763,"source":{"system":"sec-edgar","filing":"0000899243-21-035417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321035417/doc4.xml","form_type":"4"}},{"id":2574265,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-09-09T20:15:18.000Z","date":"2021-09-08","kind":"exercise","acquired":true,"shares":15000,"price":4.3,"value":64500.0,"ownership":{"direct":true},"balance_after":17250,"source":{"system":"sec-edgar","filing":"0000899243-21-035417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321035417/doc4.xml","form_type":"4"}},{"id":2906845,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-14T22:30:07.000Z","date":"2021-01-12","kind":"purchase","acquired":true,"shares":2250,"price":21,"value":47250.0,"ownership":{"direct":true},"balance_after":2250,"source":{"system":"sec-edgar","filing":"0000899243-21-002047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321002047/doc4.xml","form_type":"4"}},{"id":2910411,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":30677,"kind":"person","name":"Trigilio Jeffrey","position":1,"cik":"0001838671","reported_name":"Trigilio Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-11T22:33:13.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":146665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 146,665 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer."}],"balance_after":146665,"derivative":{"exercise_price":21,"expiration_date":"2031-01-06","underlying":"Common Stock","underlying_shares":146665},"source":{"system":"sec-edgar","filing":"0000899243-21-001361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321001361/doc4.xml","form_type":"4"}}]}